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Abstract
Background:  Artesunate (AS) plus amodiaquine (AQ) is one artemisinin-based combination
(ACT) recommended by the WHO for treating Plasmodium falciparum malaria. Fixed-dose AS/AQ
is new, but its safety and efficacy are hitherto untested.
Methods: A randomized, open-label trial was conducted comparing the efficacy (non-inferiority
design) and safety of fixed (F) dose AS (25 mg)/AQ (67.5 mg) to loose (L) AS (50 mg) + AQ (153
mg) in 750, P. falciparum-infected children from Burkina Faso aged 6 months to 5 years. Dosing was
by age. Primary efficacy endpoint was Day (D) 28, PCR-corrected, parasitological cure rate.
Recipients of rescue treatment were counted as failures and new infections as cured. Documented,
common toxicity criteria (CTC) graded adverse events (AEs) defined safety.
Results: Recruited and evaluable children numbered 750 (375/arm) and 682 (90.9%), respectively.
There were 8 (AS/AQ) and 6 (AS+AQ) early treatment failures and one D7 failure (AS+AQ).
Sixteen (AS/AQ) and 12 (AS+AQ) patients had recurrent parasitaemia (PCR new infections 10 and
6, respectively). Fourteen patients per arm required rescue treatment for vomiting/spitting out
study drugs. Efficacy rates were 92.1% in both arms: AS/AQ = 315/342 (95% CI: 88.7–94.7) vs.
AS+AQ = 313/340 (95% CI: 88.6–94.7). Non-inferiority was demonstrated at two-sided α = 0.05:
Δ (AS+AQ – AS/AQ) = 0.0% (95% CI: -4.1% to 4.0%). D28, Kaplan Meier PCR-corrected cure rates
(all randomized children) were similar: 93.7% (AS/AQ) vs. 93.2% (AS+AQ) Δ = -0.5 (95% CI -4.2
to 3.0%). By D2, both arms had rapid parasite (F & L, 97.8% aparasitaemic) and fever (97.2% [F],
96.0% [L] afebrile) clearances.
Both treatments were well tolerated. Drug-induced vomiting numbered 8/375 (2.1%) and 6/375
(1.6%) in the fixed and loose arms, respectively (p = 0.59). One patient developed asymptomatic,
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CTC grade 4 hepatitis (AST 1052, ALT 936). Technical difficulties precluded the assessment and
risk of neutropaenia for all patients.
Conclusion: Fixed dose AS/AQ was efficacious and well tolerated. These data support the use of
this new fixed dose combination for treating P. falciparum malaria with continued safety monitoring.
Trial registration: Current Controlled Trials ISRCTN07576538
Background
Drug-resistant Plasmodium falciparum has rendered many
anti-malarial drugs ineffective with a consequential
increase in childhood morbidity and mortality, especially
in Africa [1-3]. Many countries, most of them in Africa, are
now using artemisinin-based combination therapy (ACT)
following the demonstration of their superiority over
standard monotherapies and the subsequent recommen-
dation by the World Health Organization (WHO) [4,5].
The rationale for using ACT is based on the concept that
the artemisinin will substantially and rapidly reduce even
multidrug-resistant P. falciparum parasitaemia, leaving the
residual parasitaemia to be killed by high concentrations
of the partner drug. In this way, the probability of the
development of de novo resistance is greatly reduced [6].
ACT also reduces gametocyte carriage and infectivity
[5,7,8]. Artesunate and mefloquine has reduced P. falci-
parum transmission in the low transmission areas of the
Thai-Burmese border [9] and artemether/lumefantrine
(Coartem®) has also contributed to transmission reduc-
tion in KwaZulu Natal [10].
The WHO considers rapid and effective treatment with an
ACT essential in its quest to roll back malaria [4]. Another
element considered essential is treatment compliance.
There is increasing acceptance that compliance is
improved by the use of simplified, fixed-dose combina-
tions presented in easy-to-use packaging [11,12]. Cur-
rently, the combination treatment artemether/
lumefantrine is the only fixed dose combination regis-
tered to international standards that is widely available in
malaria-endemic countries, but artesunate/mefloquine
has been registered recently in Brazil and other combina-
tions are under development, notably, dihydroartemisi-
nin/piperaquine and artesunate/pyronaridine.
The efficacy of amodiaquine (AQ) combined with artesu-
nate (AS) varies in Africa, achieving high (≥ 90%) cure
rates in some countries [13-16] but lower rates in coun-
tries such as Kenya (80%), Rwanda (80%), and Tanzania
(89%) [13,17,18]. In Burkina Faso, where the failure rate
of chloroquine was 81% by Day (D) 28 in a previous trial
[19], two small studies have evaluated loose AS combined
with AQ (AS+AQ). The cure rates of AS+AQ were 100% in
33 children aged 1 to 15 and 82% in 61 children aged 6 to
10 years [20,21].
AS+AQ is generally well tolerated as treatment [13], but as
malaria prophylaxis in travellers, AQ alone caused severe
neutropaenia and severe hepatitis [22-24]. This calls for
vigilance now that some countries are using AQ+AS
widely, because repeat treatment is often required. To
date, there are few data on the risk of AQ (alone or with
AS) inducing severe neutropaenia (<1,000/microL) when
treating P. falciparum malaria. In one trial, asymptomatic
neutropaenia (<1,000/microL) on Day 28 occurred in 6%
of 153 AQ alone or AQ+AS-treated, young African chil-
dren who had normal D0 neutrophil counts [13]. In a
meta-analysis of circa 5,000 patients treated with AQ,
there were no AQ-related deaths (Olliaro, P unpublished
data).
The present study was conducted as part of the clinical
development of a new fixed-dose combination of amodi-
aquine and artesunate that aimed to make available a
new, inexpensive, simple, and blister-packed dosing regi-
men based on age [25]. Several blister packs of loose AS
and AQ are used currently in several countries in West
Africa, including Burkina Faso. Given that the transition
in drug policy from a loose to a fixed-dose combination
would be an easier option for Ministries of Health, if the
latter proved successful, it was decided to test the fixed-
dose against the loose-dose combination of AS and AQ in
children five and under, the most vulnerable group for
malaria.
Methods
Study design
This randomized, controlled, open-label study compared
the efficacy, using a non-inferiority design, and safety of a
new, fixed-dose combination of oral artesunate and amo-
diaquine (AS/AQ), to the loose dose combination
(AS+AQ), currently used in Burkina Faso. The study was
carried out in two medical centres in the Koupela health
district of Burkina Faso over two malaria seasons from
October 2004 to February 2006.
The study was approved by the Burkina Faso ethics com-
mittee for health research and the ethics committee of theMalaria Journal 2009, 8:48 http://www.malariajournal.com/content/8/1/48
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WHO and was carried out in accordance with the Interna-
tional Conference on Harmonization (ICH) Guidelines
for Good Clinical Practice. Written informed consent was
obtained from parents or guardians prior to patients com-
mencing treatment. This trial is registered at http://
www.controlled-trials.com/ISRCTN07576538.
Study conduct
Patients of both sexes, aged between six months and five
years, weighing ≥ 5 kg, with P. falciparum monoinfection
of >1,000 parasites per μL and a measured fever (axillary
temperature  ≥ 37.5°C), were included in the study.
Patients were excluded if they: (i) had features of severe
and complicated malaria [26], (ii) had taken the study
drugs or other drugs for malarial treatment within seven
days prior to inclusion (or within three days if an artem-
isinin), or (iii) if they were receiving treatment of antibi-
otics with anti-malarial activity.
A randomization list was generated by a computer in
blocks of 50. Individual treatment allocations were kept
in sealed envelopes and opened after patients were admit-
ted into the study. All treatments were administered by a
study nurse. AS/AQ was administered according to a
newly designed, age-based dosing regimen [25], and
AS+AQ according to the manufacturer's instructions for
the Arsucam® blister pack (sanofi-aventis, Paris, France).
For both regimens, the target doses for AS and AQ base are
4 mg per kg per day and 10 mg per kg per day, respectively,
with newly defined, therapeutic ranges of 2 to 10 mg per
kg per day and 7.5 to 15 mg per kg per day.
The fixed tablet contained 25 mg of AS and 67.5 mg of
AQ. The dose was one (aged <12 months) or two (aged 12
to 60 months) tablets. The loose blister pack contained 50
mg tablets of AS (Arsumax® , sanofi-aventis) and 153 mg
tablets of AQ (Flavoquine® , sanofi-aventis). The dose was
half or one tablet of both drugs for the ages, as described
above. Patients remained in the health centre for an hour
following each treatment administration. Vomiting dur-
ing this observation period resulted in re-administration
of the same dose of study drugs.
Following the first visit (D0), patients were seen after 24
hours (D1), 48 hours (D2), 72 hours (D3), 7 days (D7),
14 days (D14), 21 days (D21) and 28 days (D28) for clin-
ical (symptoms, temperature) and parasitological
(Giemsa-stained thick films and PCR blots [except D1 for
both]) assessments. Parasite density was determined by
counting the number of asexual parasites per 200 leuco-
cytes on a Giemsa-stained thick film and expressed as the
number per μL, assuming a leucocyte count of 8,000 per
μL. If up to 500 parasites had been counted before reach-
ing 200 leucocytes, the counting process was stopped at
the end of the last field. Gametocytes were counted and
expressed as the number per 1,000 leucocytes (thick film).
Routine haematology (Pentra 60®  ) and biochemistry
(Hospitex Screen Master Tecno® ) blood samples were
taken and analysed on D0, D7, and D28.
Patients failing or not tolerating their treatment were
withdrawn from the study and rescued with 25 mg per kg
per day of oral or parental quinine base in three divided
doses for seven days. There was a systematic investigation
of all patients lost in follow-up.
Primary endpoint
The primary efficacy endpoint was the PCR-corrected par-
asitological cure rate (also known as Adequate Clinical
and Parasitological Response [ACPR]) based on a per pro-
tocol defined analysis population (see below). The criteria
for treatment failure followed broadly those of the WHO
[27]: (i) signs of severe malaria or danger signs at any time
during follow up, (ii) parasitaemia at D2>D0, (iii) D3
parasitaemia ≥ 25% of that measured on D0, (iv) D7 par-
asitaemia, and (v) a recurrent parasitaemia after D7 that
was a PCR-proven, recrudescent parasitaemia.
Patients with post-D7 recurrent parasitaemia were classed
as either failure or new infections by analysing sequen-
tially three parasite genes by PCR: first the merozoite sur-
face protein 2 (msp2), then merozoite surface protein 1
(msp1), and then glutamine-rich protein (glurp), accord-
ing to a previously published method [19]. A new infec-
tion was diagnosed if the allelic pattern for any one of the
loci differed completely between the baseline and recur-
rent samples. All other allelic patterns were diagnosed as
resistant infection.
Secondary endpoints
These were: (i) the D28 crude (i.e. not corrected by PCR)
parasitological cure rates, (ii) the proportions of patients
without parasitaemia on D2 and D3, (iii) the proportions
of patients with fever on D2 and D3, and (iv) the propor-
tions of patients with gametocytes during follow-up.
Safety
Safety was assessed by collecting clinical (symptoms,
signs) and routine laboratory data during follow up. An
adverse event was defined as a new symptom or sign that
developed post treatment or the exacerbation of a symp-
tom or sign present at baseline. A serious adverse event
(SAE) was one resulting in hospitalization, significant dis-
ability or death. AE severity was determined using the
Common Toxicity Criteria (US NIH, CTC v2 1999) and
graded as mild, moderate, severe, or very severe.
Sample size and statistical analysis
Sample size was calculated to demonstrate the non-inferi-
ority in efficacy of AS/AQ compared to AS+AQ at a one-Malaria Journal 2009, 8:48 http://www.malariajournal.com/content/8/1/48
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sided 5% α-level and a power of 90%. Assuming an effi-
cacy of 95% on the loose combination and a maximum
difference of 5% for the combination therapy, the calcu-
lated sample size was 326 patients per group. Estimating
a 15% reduction in sample size (e.g. loss to follow-up),
the sample size to be recruited was 374 patients per arm.
Although the study was only designed to demonstrate
non-inferiority at a one-sided 5% α-level, at the time of
analysis, non-inferiority was also demonstrated (upper
bound of the CI for the difference in cure rates <5%) using
a more stringent two-sided 5% α-level. Therefore, this arti-
cle reports the more stringent 95% CI.
Data were managed and analysed by an external clinical
research organization, according to a predefined analysis
plan. The per-protocol dataset excluded randomized
patients who: (i) did not meet study entry criteria, (ii)
took drugs with anti-malarial activity while on study, (iii)
were lost to follow up or withdrew consent. In this analy-
sis, patients withdrawn from the study for drug-induced
AEs and those who persistently spat out the study drug
were counted as treatment failures. PCR-determined new
infections were counted as cured.
A supportive analysis was carried out to assess the primary
end point on all randomized patients using the Kaplan-
Meier product limit estimates of survival, an analysis rec-
ommended by the WHO. PCR-defined resistant or new
infections and other study withdrawals (e.g. drug induced
AEs, protocol deviations) were censored at the time of
withdrawal. Patients lost to follow up were censored on
the last day they were seen. Several other preplanned sen-
sitivity analyses were carried out for robustness. Propor-
tional and continuous data were analysed with Chi-
squared (or Fisher's exact) and Wilcoxon tests, respec-
tively.
Results
A total of 750 patients were enrolled and randomized in
the study, 375 per arm. Of these, 626 patients (83.5%)
completed the study to D28. A total of 65 patients treated
with AS/AQ and 59 patients treated with AS+AQ withdrew
or were withdrawn from the study) (Figure 1).
Baseline characteristics & doses administered
shows the baseline characteristics of all recruited children.
Of the randomized patients, 345 (46.0%) were females
and 405 (54.0%) males. The mean (SD) age of patients at
baseline was 27.53 (14.72) months. There were no signif-
icant differences between treatment groups at baseline for
all variables studied, including demography (age, sex, and
ethnic group), clinical variables (weight, temperature, and
palpable spleen and liver), and the measured parasitic var-
iables and laboratory parameters, confirming adequate
randomization.
The median doses of both drugs administered are shown
in Table 2. Based on the newly defined therapeutic dosing
ranges for AS and AQ, all patients except one (fixed arm)
received a therapeutic dose of AS and 293 (78.5%, fixed
group) and 217 (57.9%, loose) received AQ doses within
the range (p < 0.0001). In the fixed group, 4 (1.1%) and
76 (20.4%) were dosed below and above the AQ range,
respectively; the corresponding figures for the loose group
were 0 and 158 (42.1%). Children under 12 months of
age received lower doses of both AS and AQ compared to
those aged 1 to 5 years (p < 0.0001).
Efficacy analyses
Fourteen patients (8 = fixed and 6 = loose) had early treat-
ment failure due to the development of severe malaria or
danger signs between D0 and D3. One patient in the
AS+AQ group who was parasite-free on D2 and D3
became parasitaemic on D7. Twenty-eight patients had
recurrent parasitaemia after D7: 16 from the AS/AQ group
and 12 from the AS+AQ group. Of these, 10 (AS/AQ) and
6 (AS+AQ) patients were classed by PCR as new infections
and 6 from each arm were classed as recrudescent infec-
tions.
Primary analysis
The PCR-corrected parasitological cure rates at D28 were
92.1% in both treatment groups, AS/AQ = 315/342 (95%
CI: 88.7–94.7) vs. AS+AQ = 313/340 (95% CI: 88.6–
Patient disposition Figure 1
Patient disposition. 1. SAE: 8 month old girl hospitalized 
for gastroenteritis. 2. Other reasons were: parent's/guard-
ian's decision; patients taking anti-malarial drugs during follow 
up.
Severe malaria = 8  
Recurrent parasitaemia = 16  
Parasitaemia on Day 7 = 0 
Spitting out study drug = 5  
Vomiting study drug = 8  
Other adverse event
1 = 1   
Lost to follow-up = 19  
Other reasons
2 = 8 
AS/AQ 
N = 375 
AS+AQ 
N = 375 
Completed the study to D28 
without parasitaemia = 310 
Did not receive intervention 
as allocated = 0 
Did not receive intervention 
as allocated =1
Completed the study to D28 
without parasitaemia = 316
Severe malaria = 6  
Recurrent parasitaemia = 12  
Parasitaemia on Day 7 = 1 
Spitting out study drug = 8  
Vomiting study drug = 6  
Other adverse event = 0   
Lost to follow-up = 14  
Other reasons
2 = 11 
N = 750 
Randomized patients Malaria Journal 2009, 8:48 http://www.malariajournal.com/content/8/1/48
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94.7), Δ (AS+AQ – AS/AQ) = 0.0% (95% CI: -4.1% to
4.0%). Results for all analysis datasets studied are pre-
sented In Table 3. As shown in Figure 2, the Kaplan Meier
cure rates at D28 were 93.7% (AS/AQ) and 93.2%
(AS+AQ) with 95% CI (AS+AQ – AS/AQ) from -4.2% to
3.0% (Wald method). All pre-planned sensitivity analyses
of the primary endpoint confirmed non-inferiority. The
crude parasitological cure rates at D28 were 89.2% (AS/
AQ) vs. 90.3% (AS+AQ) with 95% CI (AS+AQ – AS/AQ)
from -3.4% to 5.7%.
The median doses of AS and AQ received in cured patients
(N = 625) were 4.55 mg per kg and 12.75 mg per kg,
respectively. These doses were significantly higher than
the 28 patients with recurrent parasitaemia: 3.85 mg per
kg (p = 0.05) and 11.77 mg per kg (p = 0.04). However,
the differences were not significant for: (i) PCR resistant
infections (N = 12): 3.85 mg/kg (p = 0.18) and 11.77 mg/
kg (p = 0.21), and (ii) PCR new infections (N = 16): 3.98
mg per kg (p = 0.15) and 11.66 mg per kg (p = 0.10).
No significant differences were observed between the two
treatment groups in terms of the proportions of patients:
(i) aparasitaemic on D2 (F: 339/347 [97.7%] vs. L: 337/
344 (98.0%), p = 0.81] or (ii) afebrile on D2 [F: 337/347
(97.1%) vs. L: 331/344)96.2%), p = 0.51], and (ii) with
gametocytes during follow up (Figure 3).
Clinical adverse events
Both drug regimens were well-tolerated. Through direct
questioning, 76.3% (286 of 375) of patients in the AS/AQ
group reported at least one AE over 28 days, which was
similar (p = 0.61) to the percentage of patients reporting
AEs in the AS+AQ group, 74.7% (280 of 375). None of
these were probably or definitely related to the study treat-
ment. The number of patients with at least one possibly
related solicited AE was similar among the two groups
(AS/AQ group: 22 of 375 [5.9%] vs. AS+AQ group: 21 of
375 [5.6%]). The most frequently solicited AEs were
coughing, rhinitis, anorexia, diarrhoea and abdominal
pain. In total, 14 of 750 (1.9%) patients were withdrawn
from the study for drug-induced vomiting, 8 (2.1%) and
6 (1.6%) in the fixed and loose arms, respectively (p =
0.59). Of the 14 withdrawn, one received an AQ dose
below the therapeutic range, seven received AQ doses
within the therapeutic range, and six received AQ doses
Table 1: Baseline characteristics of patients receiving fixed or loose artesunate and amodiaquine
AS/AQ AS+AQ p-value
Male: n (%)* 193 (51.5) 212 (56.5) 0.16
Age (months): Mean (SD) 27.5 (14.2) 27.5 (15.2) 0.78
< 12 m n = 54 n = 59
1–5 y n = 321 n = 316
Weight (kg): Mean (SD) 10.5 (3.0) n = 373 10.4 (3.1) 0.66
Temp (°C): Mean (SD) 38.4 (0.8) 38.4 (0.9) 0.52
Splenomegaly: n (%) 37 (9.9) 38 (10.1) 0.90
Parasite count (/μL): Median (range) 14.5 (1 – 516.6) 14.2 (1 – 410) 0.78
Haemoglobin (g/dL): Mean (SD) 8.3 (1.7) n = 374 8.2 (1.7) n = 371 0.50
Total WCC (10^9/L): Mean (SD) 11.5 (5.1) n = 337 11.6 (4.8) n = 337 0.42
Platelet count (10^9/L): Mean (SD) 174.4 (112.6) n = 337 183.9 (113.4) n = 338 0.20
AST (IU/L): Mean (SD) 71.0 (71.1) n = 303 70.0 (76.3) n = 298 0.53
ALT (IU/L): Mean (SD) 31.8 (44.9) n = 299 32.0 (53.1) n = 293 0.87
Total bilirubin (μmol/L): Mean (SD) 26.0 (27.8) n = 321 25.7 (33.9) n = 311 0.77
* n = 375 unless stated
Table 2: Median (range) doses of artesunate and amodiaquine, expressed as mg/kg, administered on Day 0
AS/AQ (fixed) N = 373 AS+AQ (loose) N = 375
Age* AS
median (range)
AQ
median (range)
AS
median (range)
AQ
median (range)
0–11 months 3.57 (2.50 – 5.56) N = 54 9.64 (6.75 – 15.00) N = 54 3.57 (2.50 – 6.85) N = 59 10.86 (7.60 – 20.96) N = 59
12+ months 4.67 (1.79 – 10.00) N = 319† 12.62 (4.82 – 27.00) N = 319† 4.72 (2.50 – 10.00) N = 316 14.44 (7.65 – 30.60) N = 316
* Median doses for AS and AQ were significantly (p < 0.0001) higher comparing children <12 vs. ≥ 12 months.
† The weights of 2 patients (19 months old and 42 months old) assigned to the AS/AQ treatment group were not available. Both patients received 
2 tablets at 25/67.5 mg each on D0Malaria Journal 2009, 8:48 http://www.malariajournal.com/content/8/1/48
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above the therapeutic range; doses in the six were (i) fixed:
16.9, 21.1 mg per kg per day, and (ii) loose: 15.3, 17, 19.1,
and 23.5 mg per kg per day.
Nine patients experienced a total of 12 SAEs, including
two (0.27%) deaths. All SAEs occurred within the first
three days of treatment except for one patient, who had
gastroenteritis requiring rehydration in the hospital on
D11. Four of these patients (1.1%) were in the AS/AQ
group and five (1.3%) in the AS+AQ group (p = 0.74). In
the AS/AQ group these were: (i) one death on D1 owing
to severe malaria (D0 parasitaemia 11,224/μL), (ii) two
patients with convulsions (severe malaria) and (iii) one
child with gastroenteritis. AS+AQ SAEs were: (i) one death
on D1 owing to severe malaria (D0 parasitaemia 1651/
μL), (ii) one patient with convulsions and anaemia sec-
ondary to severe malaria, (iii) one patient with severe
prostration (severe malaria), and (iv) two patients with
acute respiratory distress, consistent with malaria-induced
metabolic acidosis or pneumonia. All SAEs were consid-
ered unrelated to the study drugs.
Laboratory parameters
Because the mean values and mean changes from baseline
were very similar in both treatment groups, laboratory
data from both arms have been combined. By D28, the
mean haematocrit increased from 26.6 to 31.2% (p  <
0.0001). The mean platelet counts rose from 179.2 to
337.6 × 109/L by D28 (p < 0.0001).
During the first malaria season (2004), the Pentra 60®
machine at the Centre National de Recherche et de Forma-
tion sur le Paludisme (CNRFP) broke down, resulting in
the full blood count (FBC) being determined at a private
laboratory, where the differential white cell counts (WCC)
were determined manually in a total of 350 patients. The
results are reported here for completeness, but are deemed
to be inaccurate because of the clear difference in the rates
of neutropaenia (defined as a neutrophil count of <1,000
per μL) and leucopaenia (WCC <6,000 per μL for children
<12 months, <5,000 per μL for children between one and
five years of age) between the two laboratories. The total
number of children (2004 and 2005 combined) with D0
and D28 neutropaenia and D0 and D28 leukopaenia
were: (i) 32 of 657 (4.9%) and 87 of 569 (15.3%), (ii) 22
of 674 (3.3%) and 34 of 569 (6.0%), respectively. Of
these totals, 28 of 32 (87.5%), 85 of 87 (97.7%), 15 of 22
(68.2%) and 33 of 34 (97.1%) were reported in 2004 by
the private laboratory. All children with reported neutro-
paenia (2004 or 2005) were well; two were mildly febrile
and only required symptomatic treatment.
Compared to D0, the mean D28 AST (70 vs. 60 IU per L,
p = 0.02) and D28 total bilirubin (25.85 vs. 13.1 μmol per
L, p < 0.0001) values fell significantly. Mean serum ALT
(32 vs. 29 IU/L) and creatinine (37 vs. 38 μmol per L) val-
ues changed little over time. Six of 529 (1.1%) patients
with D28 ALT results had CTC grade 2 raised (>2.5 to 5 ×
ULN) ALT concentrations (range 104 to 196 IU per L) and
one 2-year-old child (0.19%) in the AS+AQ group had
asymptomatic, CTC grade 4 hepatitis [AST 1052, ALT 936
IU per L]). All seven children had normal ALT values at
baseline, were clinically well and aparasitaemic with nor-
mal D28 total bilirubin values, but all had raised D28 AST
(range 73 to 1052 IU per L).
Discussion
This study has shown that amodiaquine and artesunate
taken as either a fixed- or a loose-dose combination were
highly effective for the treatment of acute, paediatric,
uncomplicated P. falciparum malaria. Efficacy rates were
~93% for both combinations and rose to 96% when chil-
dren who vomited/spat out their drugs were excluded,
exceeding the WHO-recommended 90% efficacy rate for
anti-malarial treatments [11]. Both combinations were
well tolerated with only 2% of children discontinuing
because of drug-induced vomiting.
The fixed dose regimen was compared with the loose com-
bination for three principal reasons. There was already
experience with the loose formulation in West Africa. At
the time of the study, chloroquine was the recommended
first-line treatment in Burkina Faso, but this failing drug
could not be used as a comparator. Another option could
have included the registered artemether/lumefantrine.
However, this combination did not then have a formula-
Table 3: PCR-corrected cure rates on all predefined analysis datasets
Data set AS/AQ AS+AQ Difference (95% CI)
AS+AQ – AS/AQ
PP dataset 92.1% (315/342) 92.1% (313/340) 0.0% (-4.0%, 4.1%)
Modified PP dataset1 95.7% (315/329) 96.0% (313/326) 0.3% (-2.8%, 3.3%)
Full dataset (ITT)2 85.3% (320/375) 85.9% (322/375) 0.5% (-4.5%, 5.6%)
1. The modified PP dataset excluded patients vomiting/spitting out study drug in addition to patients already excluded from the PP dataset
2. Patient withdrawals due to vomiting/spitting out study drug, refusal to take study drug, loss to follow up, patients taking anti-malarial drugs during 
follow up, etc., were counted as failures for analysis purposesMalaria Journal 2009, 8:48 http://www.malariajournal.com/content/8/1/48
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tion that was either suitable or registered for children less
than 10 kg and would have necessitated their exclusion
from this study.
This new fixed-dose combination used a new, simplified,
computer-modelled, age-based regimen that was blister
packed [25]. Making anti-malarial drug regimens user
friendly may have a positive effect on treatment adherence
[12], a crucial element in reducing the development and
spread of drug resistance caused by sub-therapeutic drug
concentrations [28]. Interestingly, the fixed dose was bet-
ter for overall dosing accuracy than the loose regimen,
which is used currently in several African countries. In this
study, the fixed regimen resulted in 1/5 of children receiv-
ing an AQ dose in excess of the upper therapeutic range
but no significant effect on tolerability was seen. The pro-
portions of under-dosed patients were small (0.3% AS,
1.1% AQ), but this may have a role in the development of
drug resistance at a population level and must be investi-
gated as part of any long-term studies.
Comparing the Burkina Faso children who participated in
this trial with the 88,000 African children up to five years
of age in the modelled, fixed-dose database [21], the
median doses received daily of AS (3.6 vs. 3.6 mg/kg [<12
m], 4.7 vs. 4.1 [children 1–5 years old], respectively) and
Kaplan Meier survival efficacy analysis of all randomized patients Figure 2
Kaplan Meier survival efficacy analysis of all randomized patients. Rates are expressed as 1 minus the rate of parasi-
tological failure.
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AQ ([9.7 vs. 9.8 mg per kg], 12.2 vs. 11.2 mg per kg,
respectively) and those who received excess AQ doses
(20.4 vs. 19%) were close, but the proportions of AQ
recipients underdosed was less in the Burkina Faso chil-
dren (1.1% vs. 13.9%). The difference in the latter is prob-
ably due to a lower rate of heavier children in the study.
This is the first clinical trial to assess the new, age-based,
fixed-dose combination; it is encouraging that the dosing
data in this study are similar to those predicted by the
model. The median doses of both drugs received in cured
patients were higher compared to patients with recurrent
parasitaemia, but significance was lost when stratified by
recrudescent and new infections. These data raise interest-
ing questions regarding dose and outcome. More detailed
analyses are planned.
The efficacy of AS and AQ depends on the level of back-
ground resistance to amodiaquine, which is also partially
cross-resistant to chloroquine in vitro [29,30]. All degrees
of chloroquine resistance are present in Burkina Faso and
clinical chloroquine resistance in Burkina Faso children
was 81% in a recent trial [19]. There are no current in vitro
resistance data for AQ from Burkina Faso and a small
study of 22 AQ-treated children (aged 1 to 15) found no
clinical resistance. Based on the results of this study, clin-
ical resistance to AQ in children under five is probably
low.
The cure rate in this study compares well with AS+AQ in
Angola, Sudan, the Democratic Republic of Congo, south-
ern Senegal, Colombia, and Uganda, where cure rates
exceeding 90% have been reported [16,31-35]. Neverthe-
less, lower rates have also been reported from Eastern
Africa where alternatives to AS and AQ are being used
[13,17,18]. This calls for continuing resistance monitor-
ing of AS and AQ in countries that currently deploy or will
deploy AS/AQ. In common with others, ASAQ was
assessed over 28 days, but the cure rate may have been
overestimated compared with 42 days of follow up [36].
Consistent with other trials, symptom and fever resolu-
tion were rapid. By D2, less than 3% of children were still
parasitaemic and less than 4% were still febrile. Similarly,
within one week, all but one child was asymptomatic.
Gametocyte carriage at baseline was higher than the ~10%
observed in an earlier trial in the same areas [19], reached
a peak of ~30% and declined slowly over time. This pro-
pensity to produce gametocytes may have been related to
anaemia and has appeared to counter the usually good
antigametocytogenic effect of the artesunate [5,13]. Stud-
ies have also shown a reduction in mosquito infectivity
consequent to reduced gametocyte carriage following
treatment with artemether/lumefantrine and AS plus
chloroquine or sulphadoxine/pyrimethamine [7,8]. The
effect on transmission of the long-term use of ACT in
hyper/holoendemic Africa is unknown and should be
investigated.
Proportion of patients with gametocytes at baseline and during follow up Figure 3
Proportion of patients with gametocytes at baseline and during follow up.
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AS+AQ was well-tolerated; only nine children suffered
serious adverse events, which were all due to either the
development of severe malaria or intercurrent illnesses.
Two of the nine children died because of severe malaria,
giving a case fatality rate of 0.27%. All children were
assessed carefully on admission and the two children who
died had low, baseline parasite counts. In such small chil-
dren, a number may have been developing clinically silent
features of severe malaria when first seen and their para-
site counts may have been increasing despite the use of the
rapidly acting artesunate. The parasitaemia threshold of
1,000/μL used is lower than the 2,000/μL recommended
by the WHO for areas of intense malaria transmission and
the parasite counts in children were consistent with many
similar studies conducted in Africa. Nevertheless, as the
use of ACT increases, trying to identify patients at risk of
developing severe malaria may be a new avenue of
research. Just over 2% of patients in this study suffered
from AEs considered to be study drug related; most were
due to drug-induced vomiting. A number of children per-
sistently spat out their tablets, making drug administra-
tion challenging. Whilst this is not an AE per se, strategies
for reducing drug refusal should be explored. No child in
the fixed combination group developed itching and, con-
sistent with other studies (<1 to 2%), only two children
(0.3%) reported itching in the loose combination group
[13,16]. This provides a contrast to some reports of the
structurally related chloroquine, which has caused itching
and/or an unpleasant prickly sensation in up to 20–67%
of patients [37-39].
In this study, there was a downward trend in the mean
AST and the total bilirubin, consistent with disease resolu-
tion, but mean ALT levels were stable over time, suggest-
ing a small disease effect on this enzyme in these children.
Using the D28 ALT values as a marker of possible AQ
hepatocellular toxicity by study end, about 1% had mod-
erate liver impairment and one child (0.19%) had severe
biochemical hepatitis with liver enzymes of circa 1,000 IU
per L. All of these children were well and none were jaun-
diced. These liver enzyme changes are also consistent with
an intercurrent, viral-induced hepatitis, but serology was
not measured. These findings have implications for the
deployment of amodiaquine because repeat dose AQ as
prophylaxis has caused severe hepatitis, sometimes in
conjunction with neutropaenia [22]. AQ will certainly be
used several times per year when deployed, especially in
areas of intense malaria transmission. Ergo, amodiaquine
safety will need to be assessed in well-designed studies of
repeat use AQ.
The current study reported a total of 87 patients (15.3%)
with neutrophil counts <1,000 per μL at D28 compared to
32 patients (4.9%) at D0. However, there was a significant
difference between the differential white cell counts meas-
ured in 2004 and 2005. In 2004, the differential white cell
count was done manually but after 2004, the count was
done using a new Pentra 60® machine. An audit of the
external laboratory and a quality control of the differen-
tial white cell counts for a sample of the slides were carried
out. It was concluded that the manual counts were not
reliable and that the haematology data should be pre-
sented separately for 2004 and 2005. Consequently, the
frequency of neutropaenia in children recruited in 2004
cannot be determined accurately. Taking the automated
derived data from CNRFP, the rate of D28 neutropaenia
(<1,000 per μL) was low (< 0.8%, n = 293). Nevertheless,
continued monitoring for neutropaenia and abnormal
liver function in studies involving amodiaquine should be
done to document their risks of occurrence and their clin-
ical features and significance.
Conclusion
This new fixed-dose combination, dosed by age, was effi-
cacious and well-tolerated. It is a good option for treating
acute uncomplicated P. falciparum malaria and should be
assessed in other malaria-endemic countries.
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